The content on this site is intended for healthcare professionals only
Video
ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Advances in prostate cancer in the last 10 years and a glimpse to the future
Prof Laura-Maria Krabbe, Prof Karim Fizazi and Prof Johann De Bono
21 Oct 2021
WCLC 2021: Epidemiology of MET Exon 14 mutations
Dr Anna Minchom, Dr Alex Spira, Prof Byoung Chul Cho and Prof Albrecht Stenzinge...
19 Oct 2021
OncoAlert and ecancer weekly round up for October 11th - October 16, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
18 Oct 2021
ESMO 2021: Latest in EGFR mutated advanced NSCLC
Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera
11 Oct 2021
First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and br...
Dr David Paul Carbone - The Ohio State University Medical Center, Ohio, USA
6 Oct 2021
ESMO 2021: PARPi data and their role in mono/combination therapies
Dr Neal Shore, Prof Fred Saad, Prof Eleni Efstathiou, Prof Andrew Armstrong
29 Sep 2021
ESMO 2021: Updates in hormone-sensitive prostate cancer
Prof Eleni Efstathiou, Prof Axel Merseburger, Prof Nicolas Mottet, Dr Elena Cast...
28 Sep 2021
Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSC...
Dr Pascale Tomasini and Dr Catherine Shu
27 Sep 2021
ESMO 2021: Breast cancer roundup
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
27 Sep 2021
[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally a...
Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain
![[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer ( Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain )](https://cdn.ecancer.org/42950-m.jpg "[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer ( Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain )")
24 Sep 2021
Drug combination shows promise in treatment-resistant advanced ovarian cancer
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
24 Sep 2021
Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
23 Sep 2021
